We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Test Detects Overdose Patients at Risk of Liver Damage

By LabMedica International staff writers
Posted on 28 Nov 2017
Paracetamol is a safe analgesic drug when taken at therapeutic doses; however, in overdose, paracetamol is hepatotoxic and is the most common cause of acute liver failure in the USA and Europe.

Current markers, serum alanine aminotransferase (ALT) activity and paracetamol concentration, lack sensitivity and specificity when measured soon after overdose such as at initial presentation to hospital. More...
These limitations are further compounded in staggered overdose, for which there is an increased acute liver injury risk, but for which treatment nomograms are not recommended.

A team of medical scientists by the University of Liverpool (Liverpool, UK) and the University of Edinburgh (Edinburgh, UK) recruited two cohorts to assess the potential for biomarkers to stratify patients who overdose with paracetamol. The team completed two independent prospective studies: a derivation study (MAPP) in eight UK hospitals and a validation study (BIOPAR) in ten UK hospitals. Patients in both cohorts were adults (≥18 years in England, ≥16 years in Scotland), were diagnosed with paracetamol overdose.

Blood sample taken at first presentation to hospital was stored at −80 °C as plasma or serum. All blood results from the first hospital admission were recorded (paracetamol, alkaline phosphatase, γ-glutamyl transferase, bilirubin, creatinine, and alanine aminotransferase (ALT) concentration, prothrombin time, and international normalized ratio [INR]). The primary endpoint was acute liver injury indicating need for continued acetylcysteine treatment beyond the standard course (ALT activity >100 U/L.

The reference standard of injury was ALT concentration. MicroRNA-122 (miR-122), high mobility group box-1 (HMGB1), caspase-cleaved keratin-18 (K18), full-length K18, and glutamate dehydrogenase (GLDH) were measured in the admission blood sample, with miR-122 measured by polymerase chain reaction (PCR) and other markers measured by enzyme-linked immunosorbent assay (ELISA). Each biomarker was measured in each sample in duplicate. miR-122 concentration was expressed with reference to the circulating microRNA let-7d as the internal microRNA normalizer.

The team reported that between June 2, 2010, and May 29, 2014, 1,187 patients who required acetylcysteine treatment for paracetamol overdose were recruited (985 in the MAPP cohort; 202 in the BIOPAR cohort). In the derivation and validation cohorts, acute liver injury was predicted at hospital presentation by miR-122, HMGB1, and full-length K18, and results were similar in the validation cohort. A combined model of miR-122, HMGB1, and K18 predicted acute liver injury better than ALT alone.

James W Dear, FRCP, the lead author of the study, said, “Paracetamol overdose is very common and presents a large workload for already over-stretched Emergency Departments. These new blood tests can identify who will develop liver injury as soon as they first arrive at hospital. This could transform the care of this large, neglected, patient group.” The study was published on November 13, 2017, in the journal Lancet Gastroenterology & Hepatology.

Related Links:
University of Liverpool
University of Edinburgh

Gold Member
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Autoimmune Disease Diagnostic
Chorus ds-DNA-G
New
Pan-Cancer Panel
TruSight Oncology 500
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Molecular Diagnostics

view channel
Image: The RNA-seq based diagnostic test for pediatric leukemia ensures better outcomes for children with this common cancer (Photo courtesy of Qlucore)

RNA-Seq Based Diagnostic Test Enhances Diagnostic Accuracy of Pediatric Leukemia

A new unique test is set to reshape the way Acute Lymphoblastic Leukemia (BCP-ALL) samples can be analyzed. Qlucore (Lund, Sweden) has launched the first CE-marked RNA-seq based diagnostic test for pediatric... Read more

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.